PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics

PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics

The article discusses a literature review reflecting the importance of identifying novel biomarkers in cardiology for improving conventional methods for diagnosing and stratifying risk in patients with acute coronary syndrome (ACS). Recently, more and more studies have published on such markers, in...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yu. A. Drenina, K. Yu. Nikolaev
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2020-09-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	acute coronary syndrome acute myocardial infarction proprotein convertase subtilisin/kexin type 9
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/2484
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01)

Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease
by: Haixia Tang, et al.
Published: (2025-08-01)

PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01)

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
by: Xiaocui Chen, et al.
Published: (2025-03-01)

Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
by: Zhenzhen Li, et al.
Published: (2024-11-01)

Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES
by: Gregory P. Geba, et al.
Published: (2024-12-01)

Human PCSK9D374Y exacerbates methionine choline deficiency diet-induced nonalcoholic steatohepatitis in mice
by: Abidan·ABUDURUSULI, CHEN Xiaocui, CUI Yuanfeng, Tuoluonayi·MIJITI, DENG Lihui, CHEN Bangdang
Published: (2025-05-01)

Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects
by: Ajoy Basak
Published: (2025-03-01)

Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia
by: Hongyan Jiang, et al.
Published: (2024-12-01)

MicroRNA-1912 regulates cholesterol homeostasis by targeting PCSK9
by: Chan Joo Lee, et al.
Published: (2025-09-01)

Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9
by: Marcella Palumbo, et al.
Published: (2025-03-01)

Increased serum PCSK9 levels are associated with renal function impairment in patients with type 2 diabetes mellitus
by: Zhicai Feng, et al.
Published: (2023-12-01)

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors
by: Je-Wen Liou, et al.
Published: (2024-09-01)

The importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection
by: Omer Qutaiba B. Allela, et al.
Published: (2024-12-01)

Association of Insomnia, Lipid Profile, and Lipid-Lowering Medications: A Narrative Review
by: Fang Jia, et al.
Published: (2025-01-01)

PCSK9 promotes T helper 1 and T helper 17 cell differentiation by activating the nuclear factor‐κB pathway in ankylosing spondylitis
by: Jianfei Cai, et al.
Published: (2023-05-01)

Subtilisin/kexin type 9 protein convertase and interleukin 1 beta alterations in acute myocardial infarction
by: Michał Majewski, et al.
Published: (2025-05-01)

Proprotein convertase subtilisin/kexin type 9: a promising marker of cardiovascular risk in post-menopausal diabetic women in primary prevention
by: Michelangelo Rottura, et al.
Published: (2025-03-01)

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
by: A. A. Nekipelova, et al.
Published: (2023-09-01)

The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk
by: Natalie Schellack, et al.
Published: (2016-01-01)

Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials
by: Antonio J. Vallejo‐Vaz, et al.
Published: (2018-09-01)

Outpatient Practice of Lipid-Lowering Therapy Prescription (According to the ARGO-3 Study)
by: M. V. Ezhov, et al.
Published: (2023-05-01)

Inclisiran for the treatment of hypercholesterolaemia
by: Joel C Marrs, et al.
Published: (2024-11-01)

Remnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease
by: Xi Li, et al.
Published: (2025-02-01)

Atherosclerosis and inflammation: therapeutic targets and ways of correction
by: A. A. Klimenko, et al.
Published: (2024-06-01)

Exploring the therapeutic potential of precision medicine in rare genetic obesity disorders: a scientific perspective
by: Tinh-Hai Collet, et al.
Published: (2024-12-01)

Matrix metallopeptidase 9 and outcome prediction in patients with acute coronary syndrome
by: A. O. Bilchenko, et al.
Published: (2022-10-01)

Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome
by: A. M. Namitokov, et al.
Published: (2024-04-01)

PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome
by: Wang Liang, et al.
Published: (2025-01-01)

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders
by: O. L. Barbarash, et al.
Published: (2020-09-01)

Acute Coronary Syndrome and Suicide: A Case‐Referent Study
by: Chao‐Han Liu, et al.
Published: (2016-12-01)

Short-term effects of PCSK-9 inhibitors on percutaneous coronary intervention in patients with acute coronary syndrome
by: Dong Hyun Gim, et al.
Published: (2025-05-01)

LIS-3 Acute Coronary Syndrome Registry: Changes in Clinical and Demographic Characteristics and Tactics of Prehospital and Hospital Treatment of Surviving Patients After Acute Coronary Syndrome Over a 4-Year Period
by: S. Yu. Martsevich, et al.
Published: (2020-05-01)

PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01)

Modified Diagnostic Criteria Tools for Familial Hypercholesterolemia without the Requirement for Clinical Genetic Testing: Rationale and Design of the MOOCS Adaptive Clinical Trial
by: Satyanarayana Upadhyayula
Published: (2024-10-01)

IMMUNOMARKERS IN ACUTE CORONARY SYNDROME UPON ADMISSION AND ITS TRANSITION TO MYOCARDIAL INFARCTION
by: Marzhanat G. Alieva
Published: (2017-12-01)

Mutual mediation effects of homocysteine and PCSK9 on coronary lesion severity in patients with acute coronary syndrome: interplay with inflammatory and lipid markers
by: Ping Jin, et al.
Published: (2025-01-01)

Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis
by: Guoying Kao, et al.
Published: (2025-08-01)

FEATURES OF CURRENT ACUTE CORONARY OF A SYNDROME/ACUTE MYOCARDIAL INFARCTION AT THE WOMEN IN ONE OF AREAS OF CITY OF TASHKENT (fragment of the register ACS/AMI)
by: D. E. Abidova, et al.
Published: (2017-03-01)